期刊文献+

PI3K/AKT信号通路相关蛋白表达与乳腺癌淋巴转移相关性分析 被引量:5

Relationship between the expression of PI3K/AKT signal pathway related proteinand breast cancer lymphatic metastases
原文传递
导出
摘要 目的:探讨磷脂酰肌醇3-激酶(PI3K)、丝苏氨酸蛋白激酶B(AKT)和血管内皮生长因子受体3(VEGFR-3)在人乳腺癌组织中的表达及其在淋巴转移中的作用。方法:选取60例乳腺癌组织,应用免疫组织化学SP法检测PI3K、AKT和VEGFR-3蛋白的表达,RT-PCR检测PI3K、AKT和VEGFR-3mRNA的表达,并分析其相关性。结果:PI3K在有淋巴结转移组的阳性表达率为78.13%,明显高于无淋巴结转移组53.57%,χ2=4.051 3,P=0.044 1;AKT在有淋巴结转移组的阳性表达率71.88%,明显高于无淋巴结转移组50.00%,χ2=4.029 0,P=0.044 7;VEGFR-3在有淋巴结转移组的阳性表达率为96.89%,明显高于无淋巴结转移组75.00%,χ2=4.435 7,P=0.035 2。60例新鲜标本中,PI3K、AKT和VEGFR-3mRNA在有淋巴结转移的乳腺癌组织中相对表达量分别为0.39±0.17、0.48±0.18和0.42±0.15,明显高于无淋巴结转移组0.31±0.13、0.29±0.23和0.32±0.21,组间比较差异有统计学意义,P值分别为0.047 5、0.000 7和0.036 4。经直线相关分析,PI3K阳性表达组中VEGFR-3的表达为95.00%,PI3K阴性表达组中VEGFR-3表达为70.00%;AKT阳性表达组中VEGFR-3的表达为94.59%,AKT阴性表达组中VEGFR-3的表达为73.91%,在乳腺癌组织中PI3K与VEGFR-3表达呈正相关,r=0.368 5,P=0.003 8;AKT与VEGFR-3表达也呈正相关,r=0.4154,P=0.001。结论:PI3K、AKT和VEGFR-3在乳腺癌组织中的表达呈正相关,PI3K和AKT的表达上调可能促使乳腺癌细胞VEGFR-3过表达,诱导淋巴管生成,促进淋巴转移的发生。 OBJECTIVE:To explore the expression of PI3K,AKT and VEGFR-3 in human breast cancer tissues and its role in lymphatic metastases. METHODS: Totally 60 cases of breast cancer tissues were selected, the expression of PI3K, AKT and VEGFR 3 protein was detected by using immunohistochemistry SP method,and the expression of PI3K, AKT and VEGFR-3 mRNA was detected by using RT-PCR method,and its correlation was analyzed. RESULTS: The ex pression rate of PI3K in lymph node positive group was 78. 13% ,significantly higher than the expression rate of lymph node negative group 53.57% (X2 =4.0513,P=0. 0441) ;The expression rate of AKT in lymph node positive group was 71. 88 % , which was significantly higher than that of lymph node negative group 50.00%,X2=4.0290,P=0. 044 7;The expression rate of VEGFR-3 in lymph node positive group was 96.89 %, which was significantly higher than the expression rate of lymph node negative group 75.00% (X2 =4. 435 7,P=0. 035 2). In the 60 cases of fresh breast cancer tissue specimen, the relative expression of PI3K, AKT and VEGFR-3mRNA in lymph node positive group were 0.39±0. 17,0.48±0.18 and 0. 42 ±0. 15,which was significantly 0.31±0.13,0.29±0.23 and0.32±0.21. There was higher than the relative expression of lymph node negative group a significant difference between the two groups,P were 0. 047 5, 0. 000 7 and 0. 036 4 respectively. Through the linear correlation analysis,the expression rate of VEGFR 3 in PI3K positive group was 95. 00%, the expression rate of VEGFR-3 in PI3K negative group was 70. 00%, the expression rate of VEGFR-3 in AKT positive group was 94.59% ,the expression rate of VEGFR-3 in AKT negative group was 73.91 % ,and there was positively correlation between PI3K and VEGFR-3 in breast cancer tissues (r= 0. 368 5, P = 0. 003 8). There was a positively correlated between AKT and VEGFR-3 in breast cancer tissue too (r=0. 415 4,P=0. 001). CONCLUSIONS.. The expression of PI3K, AKT and VEGFR-3 in breast cancer tissues is positive correlation. The rising expression of PI3K and AKT may promote the over expression of VEGFR-3 in breast cancer cells,induce the lymphatic generation, and promote the occurrence of lymphatic metastases.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第8期600-603,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 山东省自然科学基金(ZR2009CM039) 山东省医药卫生科技发展计划(2011HW084)
关键词 乳腺肿瘤 淋巴转移 淋巴管生成 磷脂酰肌醇3-激酶 丝苏氨酸蛋白激酶B 血管内皮生长因子受体3 breast cancer lymphatic metastases lymphatic generation PI3K/AKT signal pathway VEGFR 3
  • 相关文献

参考文献9

二级参考文献55

共引文献52

同被引文献49

  • 1郑颖娟,王辉,刘晓静,梁天嵩,赵静宜,翟素娜,张羲茜,杨道科.人参皂苷对Luminal型乳腺癌中Fas、FasL表达水平的影响[J].辽宁中医杂志,2020(10):185-189. 被引量:6
  • 2金正均.合并用药中的相加[J].中国药理学报,1980,1(2):70-76.
  • 3Wickenden JA, Waston CJ. Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts[J]. Breast Cancer Res, 2010,12(2) 202-204.
  • 4De Marco C, Rinaldo N, Bruni P, et al. Multiple genetic altera tions within the PI3K pathway are responsible for AKT activa- tion in patients with ovarian earcinoma[J/CD]-. PLoS One, 2013, 8(2) :e55362.
  • 5Molife LR, Yan L, Vitfelll Rasmussen J, et al. Phase 1 trial of the oral AKT inhibitor MN-2206 plus carboplatin/paclitaxel, do- cetaxel, or erlotinib in patients with advanced solid tumors[J]. J H ematol Oncol, 2014,7 ( 1 ) : 1.
  • 6Aqarwal E, Chaudhuri A, Leiphrakpam PD, et al. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modula- tion of AIF and Ezrin in coloreetal cancer[J]. BMC Cancer, 2014,14:145.
  • 7Wilson JM, Kunnimalaiyaan S, Gamblin TC, et al. MK2206 in- hibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest[J]. J Surg Res, 2014,191 (2) : 280-285.
  • 8Lindsley CW. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target valida tion= a 2009 update[J]. Curr Top Med Chem,2010,10(4) :458-477.
  • 9Zheng ST, Flavell AR. Divinations and surprises: genetic analy sis of caspasefunction in mice[J]. Exp Cell Res, 2000,256 ( 1 ) : 67-73.
  • 10Lin YH, Chen BY, Lai WT, et al. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in o- varian cancer cells[J]. Naunyn Schmiedebergs Arch Pharmaeol, 2015,388(1) :19-31.

引证文献5

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部